Head to head
Ensign vs HCA Healthcare
Side-by-side on the measures that matter, with a plain-English read. Full detail: ENSG · HCA
ENSG
Ensign
169.22-1.65%
1-year price shape — -4% over the period
Quant Rating D · 34/100
vs
HCA
HCA Healthcare
439.17+1.61%
1-year price shape — +1% over the period
Quant Rating D · 41/100
1-year performance, rebased to 100
HCA Healthcare edges it on the scoreable measures. HCA Healthcare has the highest Quant Rating (41); HCA Healthcare has done best over the past year (+1%); HCA Healthcare trades cheapest on trailing earnings.
| ENSG | HCA | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Care Facilities | -- |
| Last price | 169.22 | 439.17 |
| Change today | -1.65% | +1.61% |
| 1-year return | -4.0% | +0.9% |
| Market cap | $9.86B | $95.08B |
| 52-week range | 141.47 – 217.76 | 353.34 – 553.56 |
| Valuation | ||
| P/E (TTM) | 26.52 | 14.73 |
| P/E percentile, own 5-yr range | 54th | 55th |
| P/B | 4.04 | -14.32 |
| Dividend yield | 0.15% | 0.68% |
| Profitability & growth | ||
| EPS (TTM) | 5.84 | 28.33 |
| Net profit (TTM) | $340.37M | $6.13B |
| Revenue (TTM) | $5.49B | $78.01B |
| Revenue growth (YoY) | +17.3% | +8.7% |
| Gross margin | 16.0% | 42.6% |
| Operating margin | 8.5% | 15.5% |
| Net margin | 6.9% | 8.8% |
| Free cash flow (TTM) | $419.09M | $6.00B |
| Ownership & sentiment | ||
| Institutional ownership | 92.4% | 94.6% |
| Insider activity (12mo) | 23 buy / 27 sell | 22 buy / 23 sell |
| Short interest (% of float) | 2.6% | 3.0% |
| Analyst consensus | 67% buy / 33% hold (3) | 64% buy / 32% hold / 5% sell (22) |
| Analyst price target | $219 (+29%) | $457 (+4%) |
| StockVane view | ||
| StockVane Quant Rating | D (34) | D (41) |
| Company | ||
| Employees | 46,000 | 320,000 |
| Founded | 1999 | 1968 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.